Daily Archives: October 26, 2017

Brazil: The biggest emerging pharmaceutical marketplace for hepatitis C virus Decision Resources.

The brand new report contains primary analysis of epidemiology and doctors study in essential pharmaceutical marketplaces of Brazil–Rio de Janeiro, Sao Paulo, Belo and Brasilia Horizonte. SOURCE Decision Resources.. Brazil: The biggest emerging pharmaceutical marketplace for hepatitis C virus Decision Resources, among the world’s leading study and advisory firms concentrating on pharmaceutical and health care issues, finds that in approximately $120 million, the hepatitis C virus medication marketplace in Brazil is one of the most significant emerging pharmaceutical marketplaces for the condition. In 2008, product sales of hepatitis C virus medicines in Brazil amounted to about 16 % of the U.S. Hepatitis C virus drug marketplace . Brazil’s larger marketplace size could be related to the country’s more developed public healthcare system that will pay for the cost of medication therapy for eligible individuals. Continue reading

In both studies.

Clinical data in simeprevir for treatment of hepatitis C individuals to be presented at EASL meeting Medivir Abdominal today announces that data will be presented on the investigational protease inhibitor simeprevir for the treatment of genotype 1 hepatitis C patients. In both studies, 50 % of sufferers receiving pegylated interferon and ribavirin by itself achieved SVR12 http://levitraenligne.net/levitra-avis-et-commentaire.html . The info will be presented this week at The International Liver Congress 2013 of the European Association for the Study of the Liver in Amsterdam, The Netherlands. The QUEST-1 and QUEST-2 data will also be discussed in an official EASL press meeting on April 24 at 11:00 a.m. Continue reading